Released May 7, 2026, after the close
10-Q filed May 8, 2026, 38 days after period end · 0001299130-26-000081
Q1 2026 · 10-Q
Revenue$37.18M$37.18M +0.1% vs Q1 2025−16.7% vs Q4 2025
Net Income-$8.28M-$8.28M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.03-$0.03 N/M vs Q1 2025no prior Q4 2025 on file
Gross Profit$12,841,000N/M
Operating Income-$8,357,000N/M
Operating Cash Flow-$44,691,000N/M
Free Cash Flowderived-$47,734,000N/M
Margins · derived
Gross margin34.5%+38.2 pt vs Q1 2025
Operating margin-22.5%+1132.0 pt vs Q1 2025
Net margin-22.3%+1124.6 pt vs Q1 2025
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $37.18M | $37.15M | $38.81M | $38.90M |
| Net Income | -$8.28M | -$426.08M | -$78.18M | -$88.02M |
| EPS Diluted | -$0.03 | -$1.44 | -$0.29 | -$0.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR